Company news

Idorsia Ltd. (SIX:IDIA) news

Idorsia Ltd. news releases on 6ix. Latest, Aug 11, 2026: Idorsia acknowledges the DEA proposal to reclassify dual orexin receptor antagonists to the lowest…

Idorsia Ltd. (SIX:IDIA) news

Press releases & updates

Idorsia acknowledges the DEA proposal to reclassify dual orexin receptor antagonists to the lowest schedule – Schedule V

QUVIVIQ sales increased 62% year-on-year as Idorsia advances key drivers of future growth

Idorsia advances global rollout of QUVIVIQ with Jamjoom Pharma partnership in Saudi Arabia and the Levant

Invitation to Idorsia's HY 2026 Financial Reporting webcast and conference call

Idorsia appoints Roland Wandeler as Chief Executive Officer

Idorsia confirms successful closing of Pharmakon loan agreement and full repayment of New Money Facility

Idorsia strengthens financial position with up to CHF 250 million loan from Pharmakon

Idorsia reports new positive results with its breakthrough C. difficile vaccine – underscoring the unique potential of its glycan technology

New analysis of Idorsia’s aprocitentan demonstrates significant and sustained reduction in albuminuria in patients with uncontrolled / resistant hypertension

Shareholders vote in favor of all proposals by the Board at Idorsia’s Annual General Meeting 2026

Idorsia reports strong Q1 2026 performance with 74% QUVIVIQ sales growth year-on-year

Idorsia issues invitation to the 2026 Annual General Meeting of Shareholders

Idorsia welcomes Amer Joseph as new Chief Medical Officer and Head of Global Clinical Development

Idorsia’s daridorexant delivers outstanding results in a Phase 2 study in children with insomnia disorder

Idorsia announces the nomination of three candidates for election to the Board of Directors

Idorsia announces management change

Idorsia expands QUVIVIQ’s global footprint through new partnership with Pharmalink

Idorsia reports strong 2025 results with QUVIVIQ sales more than doubling – further sales growth ahead with multiple pipeline catalysts in 2026

Invitation to Idorsia's FY 2025 Financial Reporting webcast and conference call

Clear route to registration positions lucerastat as the potential first oral therapy for all patients with Fabry disease

Idorsia to present long-term lucerastat data and kidney biopsy results at WORLDSymposium

Global expansion of Idorsia’s QUVIVIQ continues with EMS partnership for Latin America

Idorsia to present at J.P. Morgan 2026 Healthcare Conference

Nature Communications reports promising effect of Idorsia’s lucerastat on kidney function in Fabry disease

Idorsia initiates a proof-of-concept trial with its oral first-in-class selective CCR6 antagonist

Idorsia’s daridorexant in women during menopausal transition age with insomnia

Idorsia’s JERAYGO (aprocitentan) approved in Canada for the treatment of resistant hypertension

New Hypertension publication underscores aprocitentan’s potential in managing hypertension patients with CKD

Idorsia’s treatment for insomnia disorder wins the inaugural Prix Galien Bridges Award in the ‘Best Biotechnology & Pharmaceutical Product’ category

Idorsia’s aprocitentan improved key prognostic indicators in patients with difficult-to-control hypertension

Idorsia to present new aprocitentan insights at ASN Kidney Week & AHA Scientific Sessions

QUVIVIQ sales up >130% driving Idorsia toward profitability – 9M 2025 results

Idorsia successfully completes an upsized offering of shares – funding the company to overall profitability

Idorsia launches an offering of registered shares – to fund the company to overall profitability

Global expansion of Idorsia’s QUVIVIQ continues as Simcere launches in China

Idorsia’s JERAYGO (aprocitentan) approved in Switzerland for the treatment of resistant hypertension

Idorsia shares new analyses of daridorexant for patients with insomnia at World Sleep 2025

Idorsia highlights very low real-world abuse potential of DORA class for insomnia treatment at WSC 2025

Idorsia to collaborate with two leading academic medical centers to launch IMPACT-HTN - a US initiative to transform care for patients with difficult-to-control hypertension

Invitation to Idorsia’s aprocitentan (TRYVIO/JERAYGO) investor Q&A webcast and conference call

Idorsia furthers the science of sleep and insomnia at World Sleep 2025

Idorsia’s TRYVIO – First FDA-approved therapy to target the endothelin pathway for systemic hypertension

Idorsia successfully completes convertible bonds restructuring

TRYVIO™ (aprocitentan) now included in ACC/AHA Clinical Practice Guidelines for the treatment of hypertension

Idorsia publishes end results of repurchase offer for its 2025 and 2028 convertible bonds

TRYVIO nominated for the 2025 Prix Galien USA “Best Pharmaceutical Product”

Idorsia publishes interim results of repurchase offer for its 2025 and 2028 convertible bonds

Strong sales acceleration of QUVIVIQ drives Idorsia toward profitability – H1 2025 results

Invitation to Idorsia's HY 2025 Financial Reporting webcast and conference call with our new CEO Srishti Gupta

A factory in a lab: Idorsia's breakthrough synthetic glycan vaccine platform validated for the first time in humans